11 – 20 of 42
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study
(
- Contribution to journal › Article
-
Mark
Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls
(
- Contribution to journal › Article
- 2020
-
Mark
Short and long-term efficacy of adalimumab in ulcerative colitis : a real-life study
(
- Contribution to journal › Article
- 2019
-
Mark
Marked regional variations in the prevalence of inflammatory bowel disease in a limited geographical region are not associated with compounds in the drinking water
(
- Contribution to journal › Article
- 2018
-
Mark
A Novel Topical PPAR 3 Agonist Induces PPAR 3 Activity in Ulcerative Colitis Mucosa and Prevents and Reverses Inflammation in Induced Colitis Models
(
- Contribution to journal › Article
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
-
Mark
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article
-
Mark
Prebiotics and synbiotics in ulcerative colitis
(
- Contribution to journal › Scientific review
-
Mark
Immunopathology of Inflammatory Bowel Disease
2017)(
- Thesis › Doctoral thesis (compilation)